Sugi Predict

Sugi Predict / Compounds / SCHEMBL1152835

SCHEMBL1152835

SCHEMBL1152835

CCOC(=O)C1(C(=O)OCC)CCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ LMNA P02545 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ OPRM1 P35372 6/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ MGAM O43451 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ SI P14410 1/20 0.39
▸ MGAM2 Q2M2H8 1/20 0.39
▸ SOAT1 P35610 1/20 0.39
▸ ATM Q13315 1/20 0.38
▸ OPRD1 P41143 3/20 0.38
▸ OPRK1 P41145 3/20 0.38
▸ SLC22A1 O15245 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ ADRA1A P35348 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9806689 0.98 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1LMNAHSD17B10POLB
SCHEMBL254353 0.98 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1LMNAHSD17B10POLB
SCHEMBL713102 0.95 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1LMNAHSD17B10POLB
SCHEMBL20831146 0.92 NPSR1 (0.42) SMN1; SMN2ALDH1A1LMNAHSD17B10POLB
SCHEMBL69496 0.90 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1LMNAHSD17B10POLB
SCHEMBL18134201 0.90 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1LMNAHSD17B10POLB
SCHEMBL22698674 0.90 NPSR1 (0.41) SMN1; SMN2ALDH1A1POLBMEN1KMT2A
SCHEMBL7102497 0.89 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1LMNAHSD17B10POLB
SCHEMBL7369559 0.89 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1LMNAHSD17B10POLB
Dioxane SCHEMBL6091078 0.88 TSHR (0.46) SMN1; SMN2ALDH1A1LMNAPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117210834-A Electrochemical-based promotion of CO 2 Method for synthesizing dicarboxylic acid compound 四川大学 2023-12-12 — — CN disclosed
US-20230355629-A1 DEUTERATED DERIVATIVES OF RUXOLITINIB SUN PHARMACEUTICAL INDUSTRIES, INC. 2023-11-09 — — US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 — — US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 — — US disclosed
CN-110857276-B Chiral beta-hydroxy amide compounds and preparation method and application thereof 中国科学院化学研究所 2021-03-02 — — CN disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 — — WO disclosed
EP-3082875-B1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF GENENTECH INC (US) 2020-11-25 — — EP disclosed
US-10632210-B2 Peptidomimetic compounds and antibody-drug conjugates thereof GENENTECH, INC. (US) 2020-04-28 — — US disclosed
CN-110857276-A Chiral β -hydroxy amide compounds and preparation method and application thereof 中国科学院化学研究所 2020-03-03 — — CN disclosed
US-20190083643-A1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF GENENTECH, INC. (US) 2019-03-21 — — US disclosed
US-5292937-A Use of malonic acid derivative compounds for retarding plant growth RHONE-POULENC INC. (US) 1994-03-08 — — US disclosed
US-5194588-A Inhibitors of human leukocyte elastase, di-, tri- and tetra-peptides ICI AMERICAS INC. (US) 1993-03-16 — — US disclosed
EP-0189305-B1 PEPTIDE DERIVATIVES ICI AMERICAS INC. (US) 1992-07-29 — — EP disclosed
US-5123951-A Ethylene response inducing agent and malonic acid derivative RHONE-POULENC NEDERLAND B.V. (NL) 1992-06-23 — — US disclosed
US-5055450-A Di-, tri- and tetrapeptides as inhibitors of human leukocyte elastase ICI AMERICAS INC. (US) 1991-10-08 — — US disclosed
US-4910190-A Containing a nitrogen containing heterocycle ring structure ICI AMERICAS INC. (US) 1990-03-20 — — US disclosed
US-4792563-A Insecticidal ethers IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-12-20 — — US disclosed
EP-0266891-A1 Insecticidal ethers IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-05-11 — — EP disclosed
CN-87105345-A Tertiary amine compound — 1988-02-03 — — CN disclosed
EP-0189305-A2 Peptide derivatives ICI AMERICAS INC. (US) 1986-07-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230355629-A1 DEUTERATED DERIVATIVES OF RUXOLITINIB JAK2, JAK1, JAK3 SMN1; SMN2 2645/4885ALDH1A1 2524/4885LMNA 4131/4885
US-10632210-B2 Peptidomimetic compounds and antibody-drug conjugates thereof DNPEP, LNPEP, BCR SMN1; SMN2 3161/4885ALDH1A1 3237/4885LMNA 2897/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT SMN1; SMN2 2118/4885ALDH1A1 481/4885LMNA 2434/4885
US-20190083643-A1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF DNPEP, LNPEP, BCR SMN1; SMN2 3161/4885ALDH1A1 3237/4885LMNA 2897/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT SMN1; SMN2 2118/4885ALDH1A1 481/4885LMNA 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.